LUMOS DIAGNOSTICS HOLDINGS LIMITED (LDX)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

LDX

LDX - LUMOS DIAGNOSTICS HOLDINGS LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: -0.5
Index:

0

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.06

05 Nov
2026

0.002

OPEN

$0.06

3.45%

HIGH

$0.07

612,906

LOW

$0.06

TARGET
$0.20 233.3% upside
OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . AVE . AYA . BB1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CTE . CU6 . CVB . CYC . EBR . EIQ . EMV . EYE . FPH . IME . IMR . IPD . MX1 . NAN . ONE . PCK . PEB . PGC . PME . RAP . RMD . SHG . SLD . SOM . TRJ .
FNARENA'S MARKET CONSENSUS FORECASTS
LDX: 1
Title FY25
Actual		 FY26
Actual		 FY27
Forecast		 FY28
Forecast
EPS (cps) xxx - 0.9 - 1.2 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A N/A xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2026 FactSet UK Limited. All rights reserved
Title 202120222023202420252026
EPS Basic xxxxxxxxxxxxxxx-0.9
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx19.5 M
Book Value Per Share xxxxxxxxxxxxxxx3.5
Net Operating Cash Flow xxxxxxxxxxxxxxx1.5 M
Net Profit Margin xxxxxxxxxxxxxxx-37.54 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202120222023202420252026
Return on Capital Employed xxxxxxxxxxxxxxx-34.48 %
Return on Invested Capital xxxxxxxxxxxxxxx-24.99 %
Return on Assets xxxxxxxxxxxxxxx-16.14 %
Return on Equity xxxxxxxxxxxxxxx-34.48 %
Return on Total Capital xxxxxxxxxxxxxxx-67.67 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-2.2 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202120222023202420252026
Short-Term Debt xxxxxxxxxxxxxxx2 M
Long Term Debt xxxxxxxxxxxxxxx7 M
Total Debt xxxxxxxxxxxxxxx9 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx22 M
Price To Book Value xxxxxxxxxxxxxxx3.01

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202120222023202420252026
Capex xxxxxxxxxxxxxxx3.7 M
Capex % of Sales xxxxxxxxxxxxxxx19.24 %
Cost of Goods Sold xxxxxxxxxxxxxxx31 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx9 M
Research & Development xxxxxxxxxxxxxxx1 M
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

28/10/2026

1

Buy

$0.20

233.33%

Lumos Diagnostics announced 1Q27 sales of US$2m, down -11.1% q/q, with cash receipts of US$1.5m and an operating cash outflow of -US$4.7m, Bell Potter details.

Notably, cash of US$11.8m represents less than three quarters of funding at the current cash burn rate.

The analyst points out FebriDx commercialisation continues to gain momentum ahead of the US flu season, with live sites increasing to 265 across 29 states and a further 485 sites under evaluation, including several major urgent care groups.

Stronger sales and cash receipts in 2Q27 and 3Q27 as anticipated as seasonal demand improves, although product utilisation will be the key test of commercial success. The broker lowers its target price to $0.20 from $0.25. Buy rating retained.

FORECAST
Bell Potter forecasts a full year FY27 dividend of 0.00 cents and EPS of minus -1.20 cents.
Bell Potter forecasts a full year FY28 dividend of 0.00 cents and EPS of minus -1.00 cents.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

0

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY
Access Extra Coverage Research History >

LDX STOCK CHART

FNArena News on LDX

1
Rudi’s View: Post-August Stock Picks & Best Buys

Sep 10 2026 - Rudi's View
2
FNArena Corporate Results Monitor – 28-08-2026

Aug 28 2026 - Australia
3
Dr Boreham’s Crucible: Lumos Diagnostics

Jun 19 2023 - Small Caps
4
Australian Broker Call *Extra* Edition – Mar 21, 2023

Mar 21 2023 - Daily Market Reports
5
Australian Broker Call *Extra* Edition – Sep 06, 2022

Sep 06 2022 - Daily Market Reports

Latest Medical Equipment & Devices News

1
Strong ResMed Result Comes With Caveats

Nov 03 2026 - Australia
2
Vitrafy Eyes US Blood Breakthrough

Oct 06 2026 - Small Caps
3
Undervalued Catapult Sports Plays A Bigger Game

Sep 16 2026 - Small Caps
4
Rudi Interviewed: Bear Market Be Gone

Aug 13 2026 - Rudi's View
5
Are Headwinds Building For ResMed In FY27?

Jul 14 2026 - Australia
6
A Technical Breakout For ResMed

Jul 07 2026 - Technicals
7
Awaiting Catapult Sports’ Fundamental Re-Rating

Jun 15 2026 - Small Caps
8
Treasure Chest: Pro Medicus

Jun 04 2026 - Treasure Chest
9
Cochlear’s Shock Downgrade Raises Concerns

Apr 23 2026 - Australia
10
GLP-1s Drive Strong Quarter For ResMed

Feb 02 2026 - Australia